Haemophilia : the official journal of the World Federation of Hemophilia · 2025
Monitoring of Nonacog Beta Pegol: One-Stage Clotting Assay With Kaolin Reagent as a Practical Alternative to Chromogenic Methods.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Prudková Marie, Smejkal Petr, Chytrá Dagmar, Zavřelová Jiřina, Romanová Gabriela, Penka Miroslav, Buliková Alena
Аннотация
INTRODUCTION: Accurate monitoring of nonacog beta pegol (N9-GP) is essential to ensure appropriate treatment and to avoid under- or overdosing, which may result in clinical complications. The product's extended half-life, achieved through molecular modification, poses challenges for activity measurement, particularly when using a one-stage clotting assay (OSA). Therefore, a chromogenic substrate assay (CSA) is preferred, although it may be less practical for urgent or routine monitoring.
AIM: To evaluate OSA and CSA for N9-GP measurement, focusing on the suitability of the OSA STA CK Prest reagent on the STA R MAX analyser.
METHODS: Factor IX activity (FIX:C) of N9-GP in vitro spiked and post-infusion samples were measured using various OSA reagents and CSA across different analysers. The in vitro sample results were evaluated as percentage recovery; the OSA STA CK Prest results from both spiked and post-infusion samples were compared with those obtained by the CSA Biophen FIX.
RESULTS: Acceptable recoveries for samples spiked at concentrations of 0.04, 0.08, 0.15, 0.61 and 1.22 IU/mL were achieved using CSA Biophen FIX (mean recovery 92% with the CN 3000 analyser and 108% with the STA R MAX analyser) and OSA STA CK Prest (mean recovery 92%, range 86%-111%). STA CK Prest showed FIX:C results comparable to Biophen FIX in both in vitro and post-infusion samples.
CONCLUSIONS: STA CK Prest and Biophen FIX showed acceptable recoveries for N9-GP, with FIX:C results in good agreement in both in vitro and post-infusion samples. This supports the reliability of STA CK Prest for FIX:C measurement.
AIM: To evaluate OSA and CSA for N9-GP measurement, focusing on the suitability of the OSA STA CK Prest reagent on the STA R MAX analyser.
METHODS: Factor IX activity (FIX:C) of N9-GP in vitro spiked and post-infusion samples were measured using various OSA reagents and CSA across different analysers. The in vitro sample results were evaluated as percentage recovery; the OSA STA CK Prest results from both spiked and post-infusion samples were compared with those obtained by the CSA Biophen FIX.
RESULTS: Acceptable recoveries for samples spiked at concentrations of 0.04, 0.08, 0.15, 0.61 and 1.22 IU/mL were achieved using CSA Biophen FIX (mean recovery 92% with the CN 3000 analyser and 108% with the STA R MAX analyser) and OSA STA CK Prest (mean recovery 92%, range 86%-111%). STA CK Prest showed FIX:C results comparable to Biophen FIX in both in vitro and post-infusion samples.
CONCLUSIONS: STA CK Prest and Biophen FIX showed acceptable recoveries for N9-GP, with FIX:C results in good agreement in both in vitro and post-infusion samples. This supports the reliability of STA CK Prest for FIX:C measurement.